We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 25, 2020

Biweekly TAS-102 With Bevacizumab for Metastatic Colorectal Cancer Refractory to Standard Therapies

The Oncologist


Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
Phase Ib/II Study of Biweekly TAS-102 in Combination With Bevacizumab for Patients With Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)
Oncologist 2020 Jul 14;[EPub Ahead of Print], H Satake, T Kato, K Oba, M Kotaka, Y Kagawa, H Yasui, M Nakamura, T Watanabe, T Matsumoto, T Kii, T Terazawa, A Makiyama, N Takano, M Yokota, Y Okita, K Matoba, H Hasegawa, A Tsuji, Y Komatsu, T Yoshino, K Yamazaki, H Mishima, E Oki, N Nagata, J Sakamoto

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading